Nasdaq · Healthcare
ARS Pharmaceuticals, Inc. (SPRY)
As-reported financials and recent SEC filings for ARS Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$84.3M
Net income
$-171.3M
Net margin
—
Diluted EPS
$-1.74
ROE
-149.9%
P/E (TTM)
—
Market cap
—
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30,000 | $1.3M | $5.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-179.4M | $-3.1M | $-67.5M | $-35.5M | $-19.5M |
| Net income | $-171.3M | $8.0M | $-54.4M | $-34.7M | $-20.2M |
| Diluted EPS | $-1.74 | $0.08 | $-0.57 | $-0.43 | $-0.35 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on SPRY
Search ARS Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.